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incremental cost of HUF 143,897 over standard care. This addi-
tional cost of care resulted in an incremental 0.05 QALY gain
over the 6 months period. The incremental cost effectiveness
ratio was 2,863,913 HUF/QALY for the pimecrolimus therapy.
CONCLUSIONS: Pimecrolimus is more cost-effective than
many other health care interventions currently reimbursed by the
Hungarian National Health Fund.
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OBJECTIVES: To evaluate short-term and long-term cost-
effectiveness of imiquimod versus surgery in the treatment of
superﬁcial basal cell carcinoma in The Netherlands. METHODS:
A decision analytic model adopting a societal perspective was
developed and compared cost and outcomes of imiquimod vs.
surgery. The short-term (18 weeks) effectiveness outcome was
histological clearance, with sustained clearance the outcome at
3 years. Direct costs included costs of excision and Moh’s
surgery, drugs, adverse events, follow-up and transportation.
Indirect costs comprise working hours lost due to dermatologist
and surgery visits. Data were derived from clinical trials
(Imiquimod histological clearance and recurrence rates), Delphi
panel (resource utilisation) and published literature (surgery
response and recurrence rates). Cost data were taken from ofﬁ-
cial costing guide and tariff lists. Two scenarios were used for
calculating surgery costs: 1) micro-costing (using average time
and supplies obtained from the Delphi panel), and 2) a Dutch
study on the costs of surgery. Long-term costs were discounted
at 4%. RESULTS: Compared with surgery, short-term savings
with imiquimod were €79 and €97 per patient for scenarios 1
and 2 respectively [total costs: €585 vs. €663 and €590 vs. €687].
Histological clearance of 82% for imiquimod and 91% for
surgery made imiquimod a cost-effective treatment option. Long-
term costs with imiquimod were an extra €148 and €133 for 
scenarios 1 and 2 [total costs: €1471 vs. €1322 and €1479 vs.
€1346], while sustained clearance with imiquimod was 87% vs.
96% for surgery. The model showed moderate sensitivity to
changes in response and recurrence rates, response to treatment,
and numbers of working days lost. CONCLUSION: While
imiquimod is cost-effective in the short-term, long-term cost-
effectiveness should be judged with prudence because of the
uncertainty surrounding long-term recurrence data. Non-tangi-
ble beneﬁts, such as patient preference for avoiding surgery and
patient convenience were not quantiﬁed in the model either.
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OBJECTIVES: To examine the cost-effectiveness (CE) of brivu-
dine over aciclovir in the treatment of herpes zoster in Germany.
METHODS: This CE analysis used effectiveness data from a
double-blind RCT comparing brivudine (125mg p.o. once daily)
with aciclovir (800mg p.o. ﬁve times daily). Treatment with
brivudine showed a 25% reduction in postherpetic neuralgia
(PHN). Based on the IMS prescription index, the 2004 incidence
of herpes zoster in Germany was 348,000 cases, with 15.74%
consecutive cases of PHN under brivudine and 21% PHN cases
under aciclovir. Cost data were obtained from public price lists.
One therapy cycle with brivudine or aciclovir costs €95.67 and
€32.83 respectively; analgesics for PHN cost an average €1500
annually. The study was conducted considering direct costs only.
A sensitivity analysis accounted for varying costs for treating
PHN and age-dependent PHN incidences. RESULTS: A total of
54,775 PHN cases under brivudine and 73,080 cases under aci-
clovir were calculated, producing total annual treatment costs of
€115,455,660 and €121,044,840. Treatment with brivudine
saved costs of €305.34 per PHN case avoided. The sensitivity
analysis considered that 60% of herpes zoster patients are 60
years or older (IMS Disease Analyzer 2002), resulting in differ-
ent numbers of PHN cases depending on age and antiviral
therapy. ICERs of brivudine ranged for the older age group
between €694.66 (PHN therapy cost: €500) and -€1805.34
(PHN therapy cost: €3000). Corresponding values for the
younger age group were €1827.66 and -€672.34. Both antiviral
therapies produced equal annual total therapy costs if PHN
therapy amounted to €1200. CONCLUSIONS: Although three
times more expensive, brivudine proved cost effective over aci-
clovir, producing savings if PHN therapy costs were equal to or
higher than €1200. Since effective analgesic therapy would cost
an average €3000 annually, brivudine may be recommended as
ﬁrst-choice treatment because of its cost-saving potential and
convenient once-daily dosage.
PSN7
EPIDEMIOLOGY AND MANAGEMENT OF EXTERNAL
GENITAL WARTS (EGW) IN FRANCE
Vainchtock A1,Aractingi S2, Monsonego J3, Sultan S4,Vernay C5,
Duru G6, Decuypere L7, Flahault A8, Lamarsalle L1,
Hamel-Gariépy L7
1IMS Health—GYD Institut, Lyon, France; 2Hôpital Tenon, Paris,
France; 3Institut Alfred Fournier, Paris, France; 4Hôpital des
Diaconesses, Paris, France; 5DAV—Conseil Général des Bouches du
Rhône, Marseilles, France; 6Universite Claude Bernard Lyon I, Lyon,
France; 7Laboratoires 3M Santé, Cergy-Pontoise, France; 8INSERM—
Unité 707, Paris, France
W
IT
HD
RA
W
N
